Get the Daily Brief
Latest Biotech News
KRAS targeted therapies: Johnson & Johnson expands into degrader-antibody conjugate space
Johnson & Johnson moved into KRAS-targeted cancer therapy with a $1 billion upfront acquisition of Firefly Bio. J&J said it is buying the startup’s Firelink degrader antibody conjugate (DAC)...
Caris accelerates operational buildout with $100M buyback while expanding NYCLAB access
Caris Life Sciences authorized a share repurchase program of up to $100 million as it continues to scale revenue from molecular profiling services. The program allows open-market and privately...
M&A reshapes lab tools for precision medicine: Standard BioTools to merge into Treeline
Standard BioTools agreed to merge with drug developer Treeline Biosciences in an all-stock transaction, with the combined company set to operate under the Treeline Biosciences name and trade on...
Precision oncology ADCs: Lonza licenses Stipple’s site-specific platform
Lonza struck a licensing deal with Stipple Bio to provide access to Stipple for multiple precision oncology antibody-drug conjugate programs. The agreement grants Stipple use of Lonza’s clinically...
GSK expands liver fibrosis target discovery with Engitix ECM models
GSK committed £44.5 million in near-term funding as part of a hepatology collaboration with Engitix aimed at identifying targets tied to liver fibrosis regression. GSK said Engitix will use its...
GSK/Engitix pact: second, related multi-target update included by source
GSK is also described as placing Engitix’s extracellular-matrix disease models into a broader, multi-target framework focused on liver biology. The agreement ties to Engitix’s disease-model...
Incyte’s late-phase bleeding disorder push: buy Star/Takeda-adjacent competitive pressure
Incyte agreed to pay $1.25 billion upfront to acquire Star Therapeutics’ subsidiary Vega Therapeutics, including a phase 3 bleeding-disorder candidate. Incyte said it will also pay $750 million...
Biotech financing: Cavalry Biosciences targets a Series B to start first clinical programs
Cavalry Biosciences is pursuing a $75 million Series B to advance its first two drug candidates into clinical testing. CEO Preston Klassen told Endpoints the funding plan is intended to support...
AI genomics infrastructure: DeepMind and Sanger launch consortium with $5M/year funding
Google DeepMind and the Wellcome Sanger Institute launched an AI genomics consortium designed to build large genomic datasets for AI-driven biological research. Google.org and DeepMind committed...
Roche/Nurix BTK degrader deal sets up a direct Lilly head-to-head
Roche agreed to pay Nurix Therapeutics $700 million upfront for rights to bexobrutideg, positioning the BTK degrader for a potential phase 3 showdown with Eli Lilly’s Jaypirca. The arrangement...
Immuno-oncology: ERAP1 inhibitor GRWD5769 plus cemiplimab shows durable activity in anti–PD-1 resistance
EMITT-1 interim data show that GRWD5769, an oral ERAP1 inhibitor, combined with cemiplimab produced durable responses across six recruited phase 1b expansion cohorts. The study evaluated patients...
Obesity pipeline: Boehringer’s survodutide faces discontinuation concerns even as execs push tolerability narrative
At ADA 2026, Boehringer Ingelheim reported that its obesity drug survodutide (licensed from Zealand Pharma) was linked to meaningful discontinuation rates in a phase 3 program. Separate conference...
Late-stage ulcerative colitis: Abivax faces malignancy overhang after positive phase 3 obefazimod results
Abivax’s stock swung after the company’s positive phase 3 ABTECT maintenance trial topline results were tempered by safety concerns flagged by analysts. The study assessed obefazimod in moderately...
CNS rare disease: Ionis awaits FDA decision after zilganersen misses secondary endpoints in Alexander disease
Ionis Pharmaceuticals’ antisense oligonucleotide zilganersen (for Alexander disease) is now awaiting an FDA decision after a pivotal phase 1–3 study met its primary endpoint but missed key...
Alzheimer’s drug discovery: ETH Zurich compound “10” targets new mechanism to slow progression
Researchers led by Ursula Quitterer at ETH Zurich reported a new small-molecule compound—“Compound 10”—that shows promise in slowing Alzheimer’s disease progression. The work targets a novel...
Precision diagnostics: portable CRISPR assay advances Mpox detection for field use
Scientists engineered a portable CRISPR-based assay designed to detect Mpox after the 2025 outbreak in Sierra Leone. The platform aims to improve on-the-ground diagnostics and epidemic containment...
Obesity competition: Lilly shares safety and tolerability updates for retatrutide
Eli Lilly disclosed additional safety and tolerability data for retatrutide at the annual meeting of the American Diabetes Association and in connection with reporting in The Lancet. The updates...
Clinical development: Pfizer monthly berobenatide shot continues to show weight-loss momentum
Pfizer presented detailed data supporting monthly dosing for berobenatide, its long-acting GLP-1 obesity drug acquired from Metsera. Results from VESPER-3 described a treatment transition from...
Oncology early development: ABBV-706 SEZ6-targeting ADC enters first-in-human testing
AbbVie initiated a first-in-human study of ABBV-706, an antibody-drug conjugate targeting SEZ6 in patients with advanced solid tumors. The program represents a new mechanism exploration for ADCs...
BTK degraders—Roche/Nurix vault into phase 3 versus Lilly’s Jaypirca
Roche moved to secure a late-stage competitive position in BTK degradation by paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg. The deal puts Roche in the center of an...